iSEND is an algorithmic model specific for advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors

被引：0
|
作者：
Park, Wungki [1 ]
Florou, Vaia [1 ]
Algaze, Sandra [1 ]
Saravia, Diana [1 ]
Kwon, Deukwoo [1 ,2 ]
Lopes, Gilberto [1 ]
机构：
[1] Univ Miami, Miami, FL USA
[2] Sylvester Comprehens Canc Ctr, Miami, FL USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P75
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer
    Li, Li
    Xu, Chunhua
    Wang, Wei
    Zhang, Qian
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (05):
  • [2] Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
    Tachihara, Motoko
    Nishimura, Yoshihiro
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S1289 - S1291
  • [3] Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
    Ferrara, Roberto
    Mezquita, Laura
    Texier, Matthieu
    Lahmar, Jihene
    Audigier-Valette, Clarisse
    Tessonnier, Laurent
    Mazieres, Julien
    Zalcman, Gerard
    Brosseau, Solenn
    Le Moulec, Sylvestre
    Leroy, Laura
    Duchemann, Boris
    Lefebvre, Corentin
    Veillon, Remi
    Westeel, Virginie
    Koscielny, Serge
    Champiat, Stephane
    Ferte, Charles
    Planchard, David
    Remon, Jordi
    Boucher, Marie-Eve
    Gazzah, Anas
    Adam, Julien
    Bria, Emilio
    Tortora, Giampaolo
    Soria, Jean-Charles
    Besse, Benjamin
    Caramella, Caroline
    JAMA ONCOLOGY, 2018, 4 (11) : 1543 - 1552
  • [4] PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
    Yu, Zhuo
    Zhang, Peiqing
    Gu, Weikuan
    Jiang, Xicheng
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (08) : 2941 - 2943
  • [5] PROGNOSTIC ROLE OF FILGRASTIM IN THE EFFECTIVENESS OF PD-1/PD-L1 INHIBITORS IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Pozo, Juan Francisco Marin
    Cid, Carmen Lucia Munoz
    Garcia, Raquel Claramunt
    Caba, Elvira Marin
    Granados, Ana Laura Ortega
    FARMACIA, 2023, 71 (03) : 556 - 562
  • [6] Impact of Clinicopathological Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients with Previously Treated Non-Small Cell Lung Cancer
    Jiang, T.
    Qiao, M.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2419 - S2419
  • [7] Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer
    Koyama, Junji
    Morise, Masahiro
    Tanaka, Ichidai
    Hori, Sho
    Matsuzawa, Reiko
    Ozone, Sachiko
    Matsushita, Akihiro
    Matsuo, Masaki
    Asano, Shuichi
    Tanaka, Taro
    Shima, Koichiro
    Kimura, Tomoki
    Sakamoto, Koji
    Kondoh, Yasuhiro
    Hashimoto, Naozumi
    JOURNAL OF CHEMOTHERAPY, 2025,
  • [8] PD-1/PD-L1 Inhibitors Increase Myocardial Infarction in Osimertinib-Treated Patients with Non-Small Cell Lung Cancer
    Zhu, L.
    Xia, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S393 - S394
  • [9] PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer
    Shankar, Bairavi
    Naidoo, Jarushka
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S4034 - S4037
  • [10] Research progression of PD-1/PD-L1 in non-small cell lung cancer
    Xing Liu
    Xiaodong Xie
    Oncology and Translational Medicine, 2017, 3 (03) : 111 - 115
12345